{"id":"F2022L00655","name":"Statement of Principles concerning malignant neoplasm of the thyroid gland (Reasonable Hypothesis) (No. 39 of 2022)","slug":"statement-of-principles-concerning-malignant-neoplasm-of-the-thyroid-gland-reasonable-hypothesis-no-","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":441369,"registerId":"F2022L00655-fast-fetch-1775956681406","compilationNumber":null,"startDate":"2026-04-12","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Statement of Principles concerning malignant neoplasm of the thyroid gland (Reasonable Hypothesis) (No. 39 of 2022)","content":"---\nmeta-content-style-type: text/css\nmeta-content-type: application/xhtml+xml; charset=utf-8\nmeta-generator: Aspose.Words for .NET 22.10.0\n---\n\n?xml version=\"1.0\" encoding=\"utf-8\" standalone=\"no\"?>\n\n![RMA-Red](image.001.jpeg)\n\n \n\nStatement of Principles\n\nconcerning\n\nMALIGNANT NEOPLASM OF THE THYROID GLAND  (Reasonable Hypothesis)\n\n(No. 39 of 2022)\n\nThe Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(2) of the Veterans' Entitlements Act 1986.\n\n \n\nDated                                           29 April 2022\n\n \n\n \n\n \n\n \n\n \n\n| The Common Seal of the  Repatriation Medical Authority  was affixed to this instrument  at the direction of:<br> |\n| --- |\n| <br> <br>Professor Terence Campbell AM<br>Chairperson<br> |\n\n\n \n\n   \n\n\nContents\n\n1 Name\n\n2 Commencement\n\n3 Authority\n\n4 Repeal\n\n5 Application\n\n6 Definitions\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n8 Basis for determining the factors\n\n9 Factors that must exist\n\n10 Relationship to service\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nSchedule 1 - Dictionary\n\n1 Definitions\n\n \n\n\n\n\n1               Name\n\nThis is the Statement of Principles concerning malignant neoplasm of the thyroid gland (Reasonable Hypothesis) (No. 39 of 2022).\n\n2               Commencement\n\n              This instrument commences on 30 May 2022.\n\n3               Authority\n\nThis instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986.\n\n4               Repeal\n\nThe Statement of Principles concerning malignant neoplasm of the thyroid gland No. 39 of 2014 (Federal Register of Legislation No. F2014L00476) made under subsections 196B(2) and (8) of the VEA is repealed.\n\n5               Application\n\nThis instrument applies to a claim to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies.\n\n6               Definitions\n\nThe terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.\n\n7               Kind of injury, disease or death to which this Statement of Principles relates\n\n(1)          This Statement of Principles is about malignant neoplasm of the thyroid gland and death from malignant neoplasm of the thyroid gland.\n\nMeaning of malignant neoplasm of the thyroid gland\n\n(2)          For the purposes of this Statement of Principles, malignant neoplasm of the thyroid gland:\n\n(a)          means a primary malignant neoplasm arising from the follicular epithelial cells of the thyroid gland; and\n\n(b)          includes:\n\n(i)            anaplastic thyroid cancer;\n\n(ii)         follicular thyroid cancer;\n\n(iii)       Hurthle cell thyroid cancer;\n\n(iv)        mixed medullary and follicular thyroid cancer;\n\n(v)          papillary thyroid cancer; and\n\n(vi)        thyroid neoplasms of uncertain malignant potential; and \n\n(c)          excludes:\n\n(i)            haematolymphoid tumours including Hodgkin's lymphoma and non-Hodgkin lymphoma;\n\n(ii)         mesenchymal tumours including soft tissue sarcoma; and\n\n(iii)       neuroendocrine tumours including medullary thyroid carcinoma.\n\n(3)          While malignant neoplasm of the thyroid gland attracts ICD‑10‑AM code C73, in applying this Statement of Principles the meaning of malignant neoplasm of the thyroid gland is that given in subsection (2).\n\n(4)          For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.\n\nDeath from malignant neoplasm of the thyroid gland\n\n(5)          For the purposes of this Statement of Principles, malignant neoplasm of the thyroid gland, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's malignant neoplasm of the thyroid gland.\n\nNote: terminal event is defined in the Schedule 1 – Dictionary.\n\n8               Basis for determining the factors\n\nThe Repatriation Medical Authority is of the view that there is sound medical‑scientific evidence that indicates that malignant neoplasm of the thyroid gland and death from malignant neoplasm of the thyroid gland can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA.\n\nNote: MRCA, relevant service and VEA are defined in the Schedule 1 – Dictionary.\n\n9               Factors that must exist\n\nAt least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting malignant neoplasm of the thyroid gland or death from malignant neoplasm of the thyroid gland with the circumstances of a person's relevant service:\n\n(1)          having received a cumulative equivalent dose of at least 0.1 sievert of ionising radiation to the thyroid gland at least 5 years before the clinical onset of malignant neoplasm of the thyroid gland;\n\nNote: cumulative equivalent dose is defined in the Schedule 1 – Dictionary.\n\n(2)          having received a cumulative equivalent dose of at least 0.05 sievert of ionising radiation to the thyroid gland by the age of 20 years and at least 5 years before the clinical onset of malignant neoplasm of the thyroid gland;\n\nNote: cumulative equivalent dose is defined in the Schedule 1 – Dictionary.\n\n(3)          having iodine-131 (radioactive iodine) therapy at least 5 years before the clinical onset of malignant neoplasm of the thyroid gland;\n\n(4)          being overweight or obese for at least 5 years before the clinical onset of malignant neoplasm of the thyroid gland;\n\nNote: being overweight or obese is defined in the Schedule 1 – Dictionary.\n\n(5)          having a thyroid condition from the specified list of thyroid conditions at the time of the clinical onset of malignant neoplasm of the thyroid gland;\n\nNote: specified list of thyroid conditions is defined in the Schedule 1 – Dictionary.\n\n(6)          having acromegaly before the clinical onset of malignant neoplasm of the thyroid gland;\n\nNote: acromegaly is defined in the Schedule 1 - Dictionary.\n\n(7)          having diabetes mellitus for at least 5 years before the clinical onset of malignant neoplasm of the thyroid gland;\n\n(8)          having an autoimmune disease from the specified list of autoimmune diseases at the time of the clinical onset of malignant neoplasm of the thyroid gland;\n\nNote: specified list of autoimmune diseases is defined in the Schedule 1 - Dictionary.\n\n(9)          undergoing organ or tissue transplantation, excluding corneal transplant, before the clinical onset of malignant neoplasm of the thyroid gland;\n\nNote: organ or tissue transplantation is defined in the Schedule 1 – Dictionary.\n\n(10)      for parous women only, inability to breast feed for a cumulative period of at least 6 months before the clinical onset of malignant neoplasm of the thyroid gland;\n\nNote: The period of breastfeeding could be cumulative over a number of pregnancies.\n\n(11)      taking clomiphene at least 5 years before the clinical onset of malignant neoplasm of the thyroid gland;\n\n(12)      inability to obtain appropriate clinical management for malignant neoplasm of the thyroid gland.\n\n10           Relationship to service\n\n(1)          The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.\n\n(2)          The factor set out in subsection 9(12) applies only to material contribution to, or aggravation of, malignant neoplasm of the thyroid gland where the person's malignant neoplasm of the thyroid gland was suffered or contracted before or during (but did not arise out of) the person's relevant service.\n\n11           Factors referring to an injury or disease covered by another Statement of Principles\n\nIn this Statement of Principles:\n\n(1)          if a factor referred to in section 9 applies in relation to a person; and\n\n(2)          that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(2) of the VEA;\n\nthen the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.\n\n \n\n \n\nSchedule 1 - Dictionary  \n\nNote:               See Section 6\n\n1               Definitions\n\nIn this instrument:\n\n                               acromegaly means a chronic disease of adults resulting from excess production of growth hormone after closure of the epiphyses.\n\n                               being overweight or obese means having a Body Mass Index (BMI) of 25 or greater.\n\nNote: BMI is also defined in the Schedule 1 - Dictionary.\n\n                               BMI means W/H2 where:\n\n(a)          W is the person's weight in kilograms; and\n\n(b)           H is the person's height in metres.\n\n                               cumulative equivalent dose means the total dose of ionising radiation received by the particular organ or tissue from external exposure, internal exposure or both, apart from normal background radiation exposure in Australia, calculated in accordance with the methodology set out in Guide to calculation of 'cumulative equivalent dose' for the purpose of applying ionising radiation factors contained in Statements of Principles determined under Part XIA of the Veterans' Entitlements Act 1986 (Cth), Australian Radiation Protection and Nuclear Safety Agency, as in force on 2 August 2017.\n\nNote 1: Examples of circumstances that might lead to exposure to ionising radiation include being present during or subsequent to the testing or use of nuclear weapons, undergoing diagnostic or therapeutic medical procedures involving ionising radiation, and being a member of an aircrew, leading to increased levels of exposure to cosmic radiation.\n\nNote 2: For the purpose of dose reconstruction, dose is calculated as an average over the mass of a specific tissue or organ. If a tissue is exposed to multiple sources of ionising radiation, the various dose estimates for each type of radiation must be combined.\n\n                               malignant neoplasm of the thyroid gland—see subsection 7(2).\n\n                                             MRCA means the Military Rehabilitation and Compensation Act 2004.\n\n                               organ or tissue transplantation means the transplantation of:\n\n(a)          all or part of an organ or tissue; or\n\n(b)          a substance obtained from an organ or tissue.\n\n                               relevant service means:\n\n(a)          operational service under the VEA;\n\n(b)          peacekeeping service under the VEA;\n\n(c)          hazardous service under the VEA;\n\n(d)          British nuclear test defence service under the VEA;\n\n(e)          warlike service under the MRCA; or\n\n(f)           non-warlike service under the MRCA.\n\nNote: MRCA and VEA are also defined in the Schedule 1 - Dictionary.\n\n                               specified list of autoimmune diseases means:\n\n(a)          Behcet disease;\n\n(b)          inflammatory bowel disease;\n\n(c)          polymyositis;\n\n(d)          Sjögren syndrome; or\n\n(e)          systemic lupus erythematosus.\n\n                               specified list of thyroid conditions means:\n\n(a)          goitre;\n\n(b)          Graves disease;\n\n(c)          Hashimoto thyroiditis;\n\n(d)          hyperthyroidism; or \n\n(e)          thyrotoxicosis.\n\n                               terminal event means the proximate or ultimate cause of death and includes the following:\n\n(a)           pneumonia;\n\n(b)           respiratory failure;\n\n(c)           cardiac arrest;\n\n(d)           circulatory failure; or\n\n(e)           cessation of brain function.\n\n                               VEA means the Veterans' Entitlements Act 1986.\n\n \n\n \n","sortOrder":0}],"analysis":{"flash_summary_failed":{"failed":true,"reason":"Unauthenticated. Configure AI_GATEWAY_API_KEY or use a provider module. Learn more: https://ai-sdk.dev/unauthenticated-ai-gateway","source":"analysis-cron"},"kimi_summary":{"content_quality":"ok","complexity_score":4,"scope_assessment":{"changed":false,"description":"This instrument maintains the established scope of Repatriation Medical Authority Statements of Principles. It replaces the 2014 version (No. 39 of 2014) with updated medical-scientific evidence but does not expand beyond the traditional purpose of establishing service-connected disability factors for veterans' compensation. The structure follows the standard template for SOPs under the VEA, with the same 12-factor format and dictionary structure typical of these instruments."},"complexity_factors":["Moderate cross-referencing: 14 defined terms in Schedule 1 Dictionary, with multiple terms referencing other defined terms (e.g., 'cumulative equivalent dose' references an external ARPANSA guide document)","Nested definitions: 'being overweight or obese' depends on 'BMI' definition; 'relevant service' spans six different service categories across two separate Acts (VEA and MRCA)","Conditional temporal requirements: 8 of the 12 factors include specific time-based conditions ('at least 5 years before', 'by the age of 20', 'cumulative period of at least 6 months')","Exclusionary definitions in section 7(2): The definition of thyroid cancer explicitly includes 6 sub-types and excludes 3 categories of tumours, requiring careful diagnostic classification","External document incorporation: ICD-10-AM Tenth Edition and ARPANSA dose calculation guide are incorporated by reference, creating dependencies outside the instrument","Gender-specific factor: Factor 9(10) applies only to 'parous women' (women who have given birth), creating a conditional applicability structure","Dual-purpose application: Instrument applies to both the disease and death from the disease, with 'terminal event' requiring separate definition"],"plain_english_summary":"This instrument sets medical rules (a Statement of Principles) for when thyroid cancer or death from it can be reasonably connected to Australian military service, replacing the 2014 version. It lists 12 medical factors that can establish that connection.\n\nIt affects veterans and current/former defence members claiming under the Veterans' Entitlements Act 1986 or the Military Rehabilitation and Compensation Act 2004. A listed factor must be shown to be related to the person’s service to qualify."},"flash_summary":{"complexity_score":6,"scope_assessment":{"changed":true,"description":"This instrument expressly repeals the 2014 Statement of Principles (section 4) and replaces it with the 2022 text. The replacement sets the operative criteria and definitions (whole instrument), but the instrument itself does not provide a line‑by‑line comparison to the prior version, so the precise nature of the scope changes must be established by comparing the two texts. Key operational effects: updated factor list (section 9), clarified diagnostic inclusions/exclusions (section 7), and reliance on an external dose‑calculation guide (Schedule 1)."},"complexity_factors":["Multiple, specific medical and exposure criteria must be assessed (see section 9(1)–(12)), increasing evidentiary complexity.","Quantitative radiation thresholds require dose reconstruction using an external methodology (Schedule 1 definition of \"cumulative equivalent dose\" referencing the ARPANSA Guide — Schedule 1).","Temporal requirements (e.g. exposures or treatments must be ≥5 years before clinical onset) create additional factual inquiries (see sections 9(1)–(3), 9(3)).","Narrowly defined inclusions and exclusions for the diagnosis require careful disease classification (see section 7(2)(a)–(c) and 7(3)).","Interplay with other Statements of Principles means overlapping conditions are governed by other instruments, requiring cross-referencing (section 11).","Service-connection rule requires the listed factor to be related to the person’s relevant service, adding causal-link assessments (section 10(1)).","Special limitation on factor 9(12) (inability to obtain appropriate clinical management) changes its operation when the disease pre‑existed service (section 10(2)), complicating causation analysis.","Several technical definitions (BMI formula, \"being overweight or obese\", definitions of organ transplantation, autoimmune and thyroid condition lists) demand precise measurement or clinical records (Schedule 1).","Repeal and replacement of the 2014 Statement (section 4) means practitioners must use the current text and cannot rely on prior formulations.","Administrative and evidentiary burden falls on claimants and decision-makers to produce or obtain clinical records, treatment histories and, for radiation, reconstructed dose estimates (sections 5, 9 and Schedule 1)."],"plain_english_summary":"This Statement of Principles sets the medical criteria the Repatriation Medical Authority uses to decide whether malignant thyroid cancer (and death from it) can be reasonably connected to a person's military service for claims under the Veterans' Entitlements Act or the Military Rehabilitation and Compensation Act. It lists specific, measurable factors — for example radiation dose thresholds, prior thyroid disease, obesity and certain treatments — that, if linked to service, are sufficient to raise a \"reasonable hypothesis\" for entitlement decisions."}},"importantCases":[],"_links":{"self":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-thyroid-gland-reasonable-hypothesis-no-","history":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-thyroid-gland-reasonable-hypothesis-no-/history","analysis":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-thyroid-gland-reasonable-hypothesis-no-/analysis","conflicts":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-thyroid-gland-reasonable-hypothesis-no-/conflicts","importantCases":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-thyroid-gland-reasonable-hypothesis-no-/important-cases","documents":"/api/acts/statement-of-principles-concerning-malignant-neoplasm-of-the-thyroid-gland-reasonable-hypothesis-no-/documents"}}